DL
Therapeutic Areas
Liquidia Corporation Pipeline
| Drug | Indication | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) | Approved (Tentative) |
| LIQ861 (treprostinil) inhalation powder | Pulmonary Arterial Hypertension (PAH) | Phase 3 |
| L606 (liposomal treprostinil) injection | Pulmonary Arterial Hypertension (PAH) and other rare pulmonary diseases | Pre-clinical |
Leadership Team at Liquidia Corporation
RA
Roger A. Jeffs, Ph.D.
Chief Executive Officer & Director
MK
Michael Kaseta
Chief Financial Officer & Treasurer
TS
Tushar Shah, M.D.
Chief Medical Officer
RJ
Robin J. Steele
Chief Commercial Officer
JA
Jason Adair
Chief Operating Officer
RS
Rajiv Shukla
Chairman of the Board
PB
Paul B. Manning
Director
JP
John P. Hamill
Director
AM
Anne M. Phillips, M.D.
Director
KG
Kelley G. Downing
Director